Lurbinectedin is responsible for DNA recognition and binding, producing double-strand DNA (dsDNA) breaks thus resulting in apoptosis. Sensitivity to lurbinectedin is linked to the nucleotide excision repair (NER) system. Furthermore, irinotecan, a topoisomerase I inhibitor, provokes dsDNA breaks that could be reinforced abrogating the NER system using lurbinectedin. BRCA-mutated patients, already treated with platinum-derived drugs, who suffered DNA damage, cannot repair the breaks due to lurbinectedin interaction, whereas irinotecan provokes a dsDNA break that promotes synthetic lethality. This article describes an exceptional response to lurbinectedin alone followed by the association with irinotecan in a BRCA-mutated platinum-resistant ovarian cancer patient. A 44-year-old BRCA1-mutated ovarian cancer patient was treated in sixth line with lurbinectedin and irinotecan with a time to further progression (TTFP) equal to 8 months. In our case, the association with irinotecan overcame the resistance to lurbinectedin alone. In conclusion, lurbinectedin and irinotecan demonstrated a promising response in platinum-resistant patients. However, further studies should be conducted to validate our findings and future trials will be important to further define the clinical utility of lurbinectedin.

1. Leal, JF, Martínez-Díez, García-Hernández, V, et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 2010; 161: 1099–1110.
Google Scholar | Crossref | Medline2. Santamaría Nuñez, G, Robles, CM, Giraudon, C, et al. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther 2016; 15: 2399–2412.
Google Scholar | Crossref | Medline3. Belgiovine, C, Bello, E, Liguori, M, et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer 2017; 117: 628–638.
Google Scholar | Crossref | Medline4. Bhatia, V, Barroso, SI, García-Rubio, ML, et al. BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2. Nature 2014; 511: 362–365.
Google Scholar | Crossref | Medline5. Poveda, A, Del Campo, JM, Ray-Coquard, I, et al. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Ann Oncol 2017; 28: 1280–1287.
Google Scholar | Crossref | Medline6. Poveda, A, Oaknin, A, Romero, I, et al. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Sci Rep 2021; 11: 4433.
Google Scholar | Crossref | Medline7. Takahashi, R, Mabuchi, S, Kawano, M, et al. Preclinical investigations of PM01183 (lurbinectedin) as a single agent or in combination with other anticancer agents for clear cell carcinoma of the ovary. PLoS One 2016; 11: e0151050.
Google Scholar | Crossref8. Rouzier, R, Gouy, S, Selle, F, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer 2017; 70: 133–142.
Google Scholar | Crossref | Medline9. Lorusso, D, Scambia, G, Pignata, S, et al. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. Ann Oncol 2016; 27: 487–493.
Google Scholar | Crossref | Medline10. Ray-Coquard, I . Trabectedin mechanism of action and platinum resistance: molecular rationale. Future Oncol 2017; 13: 17–21.
Google Scholar | Crossref | Medline11. Aix, PS, Cote, GM, Gonzalez, AF, et al. Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumors: updated results from a phase Ib-II trial. J Clin Oncol 2020; 38(Suppl. 15): 3514.
Google Scholar | Crossref12. Trigo, J, Subbiah, V, Besse, B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020; 21: 645–654.
Google Scholar | Crossref | Medline13. Cruz, C, Llop-Guevara, A, Garber, JE, et al. Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy. J Clin Oncol 2018; 36: 3134–3143.
Google Scholar | Crossref | Medline14. Gaillard, S, Oaknin, A, Ray-Coquar, IL, et al. Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: results of CORAIL trial. Ann Oncol 2018; 29(Suppl. 8): viii332.
Google Scholar | Crossref | Medline